PMID- 17424701
OWN - NLM
STAT- MEDLINE
DCOM- 20070517
LR  - 20151119
IS  - 0041-4131 (Print)
IS  - 0041-4131 (Linking)
VI  - 85
IP  - 1
DP  - 2007 Jan
TI  - [Rheumatoid arthritis: current status of therapy].
PG  - 1-8
AB  - Rheumatoid Arthritis (RA) is a frequent chronic inflammatory disease 
      characterized by distal, bilateral and symmetrical lesions, leading to joint 
      distortions and articular destructions. RA can also cause severe extra-articular 
      manifestations associated with a poor prognosis. Recent advances in the field of 
      immunopathology of RA have oriented treatment targeting the pro-inflammatory 
      cytokines like tumor necrosis factor-alpha (TNF alpha), interleukin (IL) and IL6. 
      These biotherapies are considered as an important therapeutic progress in the 
      treatment of RA acting at the level of cellular processes responsible for 
      rheumatoid disease. These new therapies are active not only in controlling the 
      disease inflammatory processes but also to stop the radiological course of RA. 
      These new therapies are however efficient as long as prescribed, their 
      interruption being rapidly followed by a flare-up of RA. Multiple adverse events 
      attributed to anti-TNF-alpha have been described especially severe opportunistic 
      infections and tuberculosis. B cells playing a critical role in sustaining the 
      chronic inflammatory process in RA, targeted depleting B cells therapies have 
      been developed in refractory forms of RA giving promising results. However, 
      before any biotherapy prescription especially of anti-TNF-alpha, an initial 
      screening should be achieved to exclude patients with history of untreated 
      tuberculosis, solid cancers, malignant hemopathies or demyelinating disorders. It 
      is also essential to assure a strict follow-up in patients under biotherapy to 
      detect adverse events that can be sometimes severe. Thus, the ratio benefit/risk 
      must be evaluated before any biotherapy prescription.
FAU - El Bahri, Dalila Mrabet
AU  - El Bahri DM
AD  - Service de Rhumatologie, Hopital La Rabta, Tunis, Tunisie.
FAU - Meddeb, Nihel
AU  - Meddeb N
FAU - Sellami, Slaheddine
AU  - Sellami S
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Actualites therapeutiques de la polyarthrite rhumatoide.
PL  - Tunisia
TA  - Tunis Med
JT  - La Tunisie medicale
JID - 0413766
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Interleukin 1 Receptor Antagonist Protein)
RN  - 0 (Interleukin-1)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab
MH  - Adrenal Cortex Hormones/administration & dosage/therapeutic use
MH  - Adult
MH  - Animals
MH  - Anti-Inflammatory Agents/administration & dosage/adverse effects/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/therapeutic use
MH  - Antibodies, Monoclonal/administration & dosage/adverse effects/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antirheumatic Agents/administration & dosage/adverse effects/therapeutic use
MH  - Arthritis, Rheumatoid/complications/drug therapy/physiopathology/*therapy
MH  - Biological Therapy/adverse effects/methods
MH  - Controlled Clinical Trials as Topic
MH  - Disease Models, Animal
MH  - Etanercept
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoglobulin G/administration & dosage/adverse effects/therapeutic use
MH  - Infliximab
MH  - Interleukin 1 Receptor Antagonist Protein/administration & dosage/adverse 
      effects/therapeutic use
MH  - Interleukin-1/antagonists & inhibitors
MH  - Receptors, Tumor Necrosis Factor/administration & dosage/therapeutic use
MH  - Risk Assessment
MH  - Spondylarthropathies/drug therapy
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
RF  - 66
EDAT- 2007/04/12 09:00
MHDA- 2007/05/18 09:00
CRDT- 2007/04/12 09:00
PHST- 2007/04/12 09:00 [pubmed]
PHST- 2007/05/18 09:00 [medline]
PHST- 2007/04/12 09:00 [entrez]
PST - ppublish
SO  - Tunis Med. 2007 Jan;85(1):1-8.